JP2024520897A - ヘモグロビン調節因子の固体形態 - Google Patents

ヘモグロビン調節因子の固体形態 Download PDF

Info

Publication number
JP2024520897A
JP2024520897A JP2023569774A JP2023569774A JP2024520897A JP 2024520897 A JP2024520897 A JP 2024520897A JP 2023569774 A JP2023569774 A JP 2023569774A JP 2023569774 A JP2023569774 A JP 2023569774A JP 2024520897 A JP2024520897 A JP 2024520897A
Authority
JP
Japan
Prior art keywords
compound
crystalline
acid
dsc
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023569774A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520897A5 (https=
Inventor
ディー． ペアレント ステファン
リー ヒューストン トラヴィス
エス． ジョンソン コートニー
ワン ファン
Original Assignee
グローバル ブラッド セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グローバル ブラッド セラピューティクス インコーポレイテッド filed Critical グローバル ブラッド セラピューティクス インコーポレイテッド
Publication of JP2024520897A publication Critical patent/JP2024520897A/ja
Publication of JP2024520897A5 publication Critical patent/JP2024520897A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
JP2023569774A 2021-05-14 2022-05-13 ヘモグロビン調節因子の固体形態 Pending JP2024520897A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163188833P 2021-05-14 2021-05-14
US63/188,833 2021-05-14
PCT/US2022/029289 WO2022241278A1 (en) 2021-05-14 2022-05-13 Solid forms of a modulator of hemoglobin

Publications (2)

Publication Number Publication Date
JP2024520897A true JP2024520897A (ja) 2024-05-27
JP2024520897A5 JP2024520897A5 (https=) 2025-05-01

Family

ID=82020064

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023569774A Pending JP2024520897A (ja) 2021-05-14 2022-05-13 ヘモグロビン調節因子の固体形態

Country Status (13)

Country Link
US (2) US11851424B2 (https=)
EP (1) EP4337659A1 (https=)
JP (1) JP2024520897A (https=)
KR (1) KR20240008356A (https=)
CN (1) CN117337285A (https=)
AR (1) AR126649A1 (https=)
AU (1) AU2022273787B2 (https=)
BR (1) BR112023021606A2 (https=)
CA (1) CA3219786A1 (https=)
MX (1) MX2023012156A (https=)
TW (1) TW202311254A (https=)
WO (1) WO2022241278A1 (https=)
ZA (1) ZA202309517B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250041312A1 (en) * 2021-12-10 2025-02-06 Global Blood Therapeutics, Inc. Methods of administering a modulator of hemoglobin
TW202515579A (zh) * 2023-06-13 2025-04-16 美商全球血液治療公司 投予血紅素的調節劑之方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020106642A1 (en) * 2018-11-19 2020-05-28 Global Blood Therapeutics, Inc. 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin
JP2024520896A (ja) * 2021-05-14 2024-05-27 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンのモジュレーターを作製する方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4432987A (en) * 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
SG10201802911RA (en) * 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020106642A1 (en) * 2018-11-19 2020-05-28 Global Blood Therapeutics, Inc. 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin
JP2024520896A (ja) * 2021-05-14 2024-05-27 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンのモジュレーターを作製する方法

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BUCAR, D. ET AL.: "Disappearing Polymorphs Revisited", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 54, no. 24, JPN6023010098, 1 June 2015 (2015-06-01), pages 6972 - 6993, ISSN: 0005770620 *
BYRN, S. ET AL.: "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations", PHARMACEUTICAL RESEARCH, vol. 12, no. 7, JPN6014008492, 1995, pages 945 - 954, ISSN: 0005770622 *
GOULD, P. L.: "Salt selection for basic drugs", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 33, JPN6013060611, 1986, pages 201 - 217, ISSN: 0005770617 *
JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 1, JPN6014023656, 1977, pages 1 - 19, ISSN: 0005770616 *
STAHLY，P.: "医薬品の塩選択,結晶多形のスクリーニングの重要性について", 薬剤学, vol. 66, no. 6, JPN6015024142, 2006, pages 435 - 439, ISSN: 0005770614 *
小嶌隆史 ほか: "医薬品開発における開発形態の最適化", ファルマシア, vol. 52(5), JPN6023009635, 2016, pages 387 - 391, ISSN: 0005770615 *
杉本 功 他: "溶媒和物、非晶質固体と医薬品製剤", 粉体工学会誌, vol. 22, no. 2, JPN6017004373, 1985, pages 85 - 97, ISSN: 0005770621 *
芦澤 一英: "塩・結晶形の最適化と結晶化技術", PHARM TECH JAPAN, vol. 18, no. 10, JPN6013060608, 2002, pages 81 - 96, ISSN: 0005770619 *
芦澤一英, 医薬品の多形現象と晶析の化学, JPN6015027444, 2002, pages 273 - 278, ISSN: 0005770618 *

Also Published As

Publication number Publication date
MX2023012156A (es) 2023-10-26
BR112023021606A2 (pt) 2023-12-19
CN117337285A (zh) 2024-01-02
ZA202309517B (en) 2024-06-26
EP4337659A1 (en) 2024-03-20
US20220363674A1 (en) 2022-11-17
US11851424B2 (en) 2023-12-26
AR126649A1 (es) 2023-11-01
US12473277B2 (en) 2025-11-18
AU2022273787B2 (en) 2025-04-03
AU2022273787A1 (en) 2023-10-26
TW202311254A (zh) 2023-03-16
US20240076290A1 (en) 2024-03-07
CA3219786A1 (en) 2022-11-17
KR20240008356A (ko) 2024-01-18
WO2022241278A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
JP7728295B2 (ja) ベルベリンウルソデオキシコール酸の固体形態ならびにその組成物および方法
AU2014239995B2 (en) Salt of omecamtiv mecarbil and process for preparing salt
US12473277B2 (en) Solid forms of a modulator of hemoglobin
KR20160118204A (ko) 2-하이드록시-6-((2-(1-이소프로필-1h-피라졸-5-일)피리딘-3-일)메톡시)벤즈알데하이드의 유리 염기의 결정성 다형체
US9221815B2 (en) Solid state form of vemurafenib choline salt
US10556896B2 (en) Crystalline forms of (3-Amino-oxetan-3-ylmethyl)-[2-(5,5-dioxo-5,6,7,9-tetrahydro-5lambda*6*-thia-8-aza-benzocyclohepten-8-yl)-6-methyl-quinazolin-4-yl]-amine
CN112020506B (zh) 新生霉素类似物与脯氨酸的共晶体形式
EP3853200B1 (en) Erbumine salt of treprostinil
HK40101540A (zh) 血红蛋白之调节剂的固体形式
WO2021001457A1 (en) Crystalline (r)-2-amino-3-phenylpropylcarbamate acid addition salts
US20230192611A1 (en) Modulators of hemoglobin
US20250304635A1 (en) Birinapant polymorph h
US12569440B2 (en) Solid formulation of a 1,2,4-oxadiazole derivative
HK40119275A (zh) 新生霉素类似物与脯氨酸的共晶体形式
CN117396460A (zh) (r)-奥昔布宁d-苹果酸盐的固体形式
HK40074169B (en) Solid formulation of a 1,2,4-oxadiazole derivative
EA043230B1 (ru) Эрбуминовая соль трепростинила
HK1224551A1 (en) Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250422

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260113